Cue Health announced strategic actions implemented by its Board of Directors to position the company for its next stage. Clint Sever, co-founder and current Chief Product Officer, has been appointed CEO, effective immediately. Sever succeeds Ayub Khattak, who is stepping down as CEO, President, and Chairman. Khattak will remain a member of the Board of Directors. The Board has appointed two strategic advisors: Paul Brown, former President and CEO of Roche Molecular Diagnostics, and Lisa Danzig, former Global Head of Medical & Scientific Affairs at Grifols – formerly Novartis Diagnostics -. Brown brings expertise in molecular diagnostics and experience with regulatory matters and evaluating and commercializing leading genomics offerings. Danzig is an expert in vaccines and has almost two decades of experience in vaccine and diagnostics development. Cue will initiate a comprehensive review of the company’s business and operations, with a focus on assessing opportunities to refine and strengthen Cue’s overarching strategy and cost structure. Clint Sever is co-founder of Cue Health and has served as Chief Product Officer since its inception.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HLTH:
Questions or Comments about the article? Write to editor@tipranks.com